(Q70997284)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

title

Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

Antonello Di Paolo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

10

M Del Tacca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

author name string

F Innocenti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

B Loru

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

C Favre

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

M Nardi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

G Bocci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

D Nardini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

P Macchia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

publication date

1 January 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

15 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

page(s)

409-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s002800050405

15 October 2019

exact match

0 references

cites work

The effect of methotrexate on the bioavailability of oral 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Studies on the xanthine oxidase activity of mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug Synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

The absorption of 6-mercaptopurine from 6-mercaptopurine riboside in rat small intestine: effect of phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Acute lymphoblastic leukemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

The treatment of acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800050405

6-Thioguanine-induced growth arrest in 6-mercaptopurine-resistant human leukemia cells.

21 January 2018

1 reference

12 December 2020

Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin.

1 reference

12 December 2020

Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography.

1 reference

12 December 2020

Immunodepressant activity and 6-mercaptopurine levels after administration of 6-mercaptopurine and azathioprine

1 reference

12 December 2020

Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases

1 reference

12 December 2020

Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey

1 reference

12 December 2020

Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy

1 reference

12 December 2020

Acute lymphoblastic leukemia: Treatment

1 reference

12 December 2020

Identifiers

DOI

10.1007/S002800050405

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8599862%20AND%20SRC:MED&resulttype=core&format=json

15 October 2019

1 reference